The ABHD17B Knockout Huh-7 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population derived from the Huh-7 human hepatocellular carcinoma cell line, designed to disrupt the ABHD17B gene. This polyclonal pool introduces loss-of-function of the ABHD17B-encoded depalmitoylase, enabling investigation of protein palmitoylation dynamics and Ras-dependent signaling in a cancer-relevant epithelial model. The engineered cells provide a genetically heterogeneous knockout background suitable for studying the effects of ABHD17B ablation without the biases of single-cell cloning, supporting population-level analyses of signaling and drug responses.
The Huh-7 host cell line was originally established from a well-differentiated hepatocellular carcinoma and retains key hepatic epithelial features, making it a widely used system for liver cancer biology, metabolic studies, and drug discovery. Huh-7 cells harbor endogenously activated Ras?CMAPK signaling and exhibit robust proliferative and migratory capacities, providing a physiologically relevant context for examining how ABHD17B-mediated depalmitoylation modulates oncogenic output.
ABHD17B functions as a serine hydrolase depalmitoylase that catalyzes the removal of palmitate groups from cysteine residues on substrate proteins, prominently including Ras GTPases (HRAS, NRAS, and KRAS). By controlling the palmitoylation state of Ras, ABHD17B dynamically regulates their subcellular trafficking between the plasma membrane, Golgi, and endomembranes, thereby fine-tuning the magnitude and localization of Ras?CMEK?CERK signaling. ABHD17B also interacts with other depalmitoylases such as LYPLA1 and LYPLA2, and its activity contributes to the broader palmitoylation cycle that orchestrates the membrane association of numerous signaling proteins. Disruption of ABHD17B is expected to increase Ras palmitoylation, potentially causing mislocalization and altered downstream activation, including changes in phospho-ERK levels.
In the context of hepatocellular carcinoma, Ras pathway hyperactivation is a frequent driver of tumor progression, and aberrant palmitoylation dynamics may further influence cancer cell behavior. The ABHD17B knockout in Huh-7 cells creates a relevant model to dissect how Ras depalmitoylation impacts HCC-relevant phenotypes such as proliferation, migration, and invasion. Since Huh-7 cells are well-characterized in drug response studies, the knockout pool also provides a platform for evaluating the therapeutic potential of modulating depalmitoylase activity in liver cancer, including combination strategies with MEK inhibitors. The polyclonal nature avoids clonal artifacts, preserving a broader spectrum of cellular responses.
Researchers can employ these ABHD17B Knockout Huh-7 Polyclonal Cells in a variety of sophisticated assays. The acyl-biotin exchange (ABE) method enables quantitative profiling of protein palmitoylation changes, while western blotting for Ras isoforms and phospho-ERK assesses signaling consequences. Confocal microscopy of fluorescently tagged Ras variants reveals altered subcellular localization patterns. Functional assays such as wound-healing migration, transwell invasion, and colony formation quantify the effects on cancer cell behavior. Additionally, these cells serve as a screening tool for small-molecule depalmitoylase inhibitors targeting ABHD17B or related enzymes. For further technical details or customization options, please contact Ascent Research.
